Latest Insider Transactions at Entasis Therapeutics Holdings Inc. (ETTX)
This section provides a real-time view of insider transactions for Entasis Therapeutics Holdings Inc. (ETTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Entasis Therapeutics Holdings Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Entasis Therapeutics Holdings Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 11
2022
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
7,598,814
+20.61%
|
$15,197,628
$2.2 P/Share
|
|
Jul 11
2022
|
Kristie Ann Wagner VP, Principal Fin & Acct Off |
SELL
Sale (or disposition) back to the issuer
|
Direct |
80,500
-100.0%
|
-
|
|
Jul 11
2022
|
Anna Diaz Triola Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
125,000
-100.0%
|
-
|
|
Jul 11
2022
|
Ruben Tommasi Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
Manoussos Perros President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
478,500
-100.0%
|
-
|
|
Jul 11
2022
|
John Patrick Mueller Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
David D. Meek Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Howard Mayer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Elizabeth M Keiley General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
David C Hastings Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Heather A. Berger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
David Altarac Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 08
2022
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
11,671,662
+35.0%
|
$23,343,324
$2.2 P/Share
|
|
Jul 07
2022
|
Ruben Tommasi Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
39,596
-100.0%
|
$79,192
$2.2 P/Share
|
|
Jul 07
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|
|
Jul 07
2022
|
Manoussos Perros President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,072
-100.0%
|
$112,144
$2.2 P/Share
|
|
Jul 07
2022
|
John Patrick Mueller Chief Development Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,092
-100.0%
|
$34,184
$2.2 P/Share
|
|
Jul 07
2022
|
David D. Meek Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Howard Mayer Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Elizabeth M Keiley General Counsel |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|
|
Jul 07
2022
|
David C Hastings Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Heather A. Berger Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
David Altarac Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|
|
Feb 24
2022
|
Kristie Ann Wagner VP, Principal Fin & Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+11.05%
|
-
|
|
Jan 18
2022
|
Anna Diaz Triola Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+50.0%
|
-
|
|
Jan 18
2022
|
David Altarac Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+42.72%
|
-
|
|
Jan 18
2022
|
David C Hastings Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+35.71%
|
-
|
|
Jan 18
2022
|
David D. Meek Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+35.71%
|
-
|
|
Jan 18
2022
|
Elizabeth M Keiley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+42.72%
|
-
|
|
Jan 18
2022
|
Heather A. Berger Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+35.71%
|
-
|
|
Jan 18
2022
|
Howard Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+35.71%
|
-
|
|
Jan 18
2022
|
John Patrick Mueller Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+42.79%
|
-
|
|
Jan 18
2022
|
Manoussos Perros President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+18.95%
|
-
|
|
Jan 18
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+42.72%
|
-
|
|
Jan 18
2022
|
Michael Gutch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+42.72%
|
-
|
|
Jan 18
2022
|
Ruben Tommasi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+39.73%
|
-
|
|
Nov 02
2021
|
Ruben Tommasi Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-5.37%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Michael Gutch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Manoussos Perros President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,704
-7.93%
|
$23,408
$2.94 P/Share
|
|
Nov 02
2021
|
John Patrick Mueller Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,907
-8.49%
|
$7,814
$2.94 P/Share
|
|
Nov 02
2021
|
David Altarac Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Elizabeth M Keiley General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Oct 19
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
David Altarac Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
David Altarac Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
Elizabeth M Keiley General Counsel |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Elizabeth M Keiley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|